Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis

Abstract

Splenomegaly is the clinical hallmark of myelofibrosis. Splenomegaly at the time of allogeneic hematopoietic cell transplantation (HCT) is associated with graft failure and poor graft function. Strategies to reduce spleen size before HCT especially after failure to Janus kinase (JAK) inhibition represent unmet clinical needs in the field. Here, we leveraged a global collaboration to investigate the safety and efficacy of splenic irradiation as part of the HCT platform for patients with myelofibrosis. We included 59 patients, receiving irradiation within a median of 2 weeks (range, 0.9–12 weeks) before HCT. Overall, the median spleen size prior to irradiation was 23 cm (range, 14–35). Splenic irradiation resulted in a significant and rapid spleen size reduction in 97% of patients (57/59), with a median decrease of 5.0 cm (95% confidence interval, 4.1–6.3 cm). The most frequent adverse event was thrombocytopenia, with no correlation between irradiation dose and hematological toxicities. The 3‐year overall survival was 62% (95% CI, 48%–76%) and 1‐year non‐relapse mortality was 26% (95% CI, 14%–38%). Independent predictors for survival were severe thrombocytopenia and anemia before irradiation, transplant‐specific risk score, higher‐intensity conditioning, and present portal vein thrombosis. When using a propensity score matching adjusted for common confounders, splenic irradiation was associated with significantly reduced relapse (p = .01), showing a 3‐year incidence of 12% for splenic irradiation versus 29% for patients with immediate HCT and 38% for patients receiving splenectomy. In conclusion, splenic irradiation immediately before HCT is a reasonable approach in patients experiencing JAK inhibition failure and is associated with a low incidence of relapse.

Myelofibrosis and allogeneic transplantation: critical points and challenges

“…Splenic irradiation represents a further alternative to splenectomy to reduce spleen size and alleviate splenic discomfort, although the results of such therapy are generally short-lasting and associated with the risk of severe cytopenias, eventually difficult to manage ( 83 ).In contrast, the results of a recent retrospective study on HSCT for MF preceded by splenic irradiation are encouraging, showing a reduced relapse after HSCT, without association between total irradiation dose and efficacy ( 84 ).…”